Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point

J Natl Cancer Inst. 1994 Jan 19;86(2):138-40. doi: 10.1093/jnci/86.2.138.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • DNA, Neoplasm / analysis*
  • Dark Adaptation / drug effects
  • Feasibility Studies
  • Female
  • Fenretinide / adverse effects
  • Fenretinide / therapeutic use*
  • Flow Cytometry
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology

Substances

  • DNA, Neoplasm
  • Fenretinide